WO2004039233A2 - Systeme et methode de detection in vivo de h. pylori - Google Patents

Systeme et methode de detection in vivo de h. pylori Download PDF

Info

Publication number
WO2004039233A2
WO2004039233A2 PCT/IL2003/000893 IL0300893W WO2004039233A2 WO 2004039233 A2 WO2004039233 A2 WO 2004039233A2 IL 0300893 W IL0300893 W IL 0300893W WO 2004039233 A2 WO2004039233 A2 WO 2004039233A2
Authority
WO
WIPO (PCT)
Prior art keywords
vivo
sensing device
stomach
patient
pylori
Prior art date
Application number
PCT/IL2003/000893
Other languages
English (en)
Other versions
WO2004039233A3 (fr
Inventor
Yoram Palti
Shlomo Lewkowicz
Yoram Ashery
Original Assignee
Given Imaging Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Given Imaging Ltd. filed Critical Given Imaging Ltd.
Priority to AU2003278576A priority Critical patent/AU2003278576A1/en
Priority to US10/532,808 priority patent/US20060052667A1/en
Publication of WO2004039233A2 publication Critical patent/WO2004039233A2/fr
Publication of WO2004039233A3 publication Critical patent/WO2004039233A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/07—Endoradiosondes
    • A61B5/073—Intestinal transmitters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14539—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring pH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/42—Detecting, measuring or recording for evaluating the gastrointestinal, the endocrine or the exocrine systems
    • A61B5/4222—Evaluating particular parts, e.g. particular organs
    • A61B5/4238—Evaluating particular parts, e.g. particular organs stomach

Definitions

  • the present invention relates to the field of in vivo diagnosis. More specifically, the present invention relates to in vivo detection of H. pylori.
  • H. pylori is a bacterium residing in the mucus lining of the stomach and duodenum. Bacteria can be found in the stomach of about half of the world population. H. pylori is believed to be the cause of gastritis, which is the underlying condition that causes ulcers and other digestive tract diseases, including cancer.
  • the stomach environment is highly acidic and contains digestive enzymes.
  • H. pylori is able to survive the severe conditions in the stomach by taking shelter in the mucus layer, which is intended to protect the stomach lining, and by creating a local micro- environment of strong bases which can neutralize the acidic gastric juices in the vicinity of the bacteria.
  • the bacterium utilizes its urease enzyme to produce strong bases by converting urea that is found in large quantities in the stomach, into bicarbonate and ammonia, both of which may be strong bases.
  • H. pylori namely, inflammation of the stomach lining
  • H. pylori increases the risk of gastric cancer and that eradication of the bacteria prevents relapses after resection of early gastric cancer.
  • infected patients going through eradicating therapy early in follow up do not develop cancer, as opposed to untreated infected patients.
  • detection, particularly early detection of the bacteria may prove to be important in management of H. pylori infection.
  • GI upper gastrointestinal
  • breath tests utilize solutions of urea containing isotopic carbon that are drunk by the patient prior to the breath test. If H. pylori is present the urea will be broken down and isotopic carbon will be detectable in the patient's breath.
  • Blood tests check for the presence of antibodies to H. pylori in a patient's blood. It is noted that antibody levels in the blood may remain high even after bacteria are no longer present in the stomach. Endoscopy usually includes taking a biopsy for later in vitro testing.
  • Embodiments of the present invention may utilize inherent H. pylori urease activity for the detection of the bacteria.
  • a method includes contacting an in vivo sensing device with the stomach wall (mucus). Endo-luminal pH in the vicinity of the mucus or any products of the urease enzymatic reaction products (e.g. ammonia and/or bicarbonate) can thus be detected by the in vivo sensing device, thereby enabling in vivo and typically in situ detection of H. pylori.
  • the in vivo sensing device is an autonomous, self contained wireless sensing device capable of transmitting in vivo data to an external receiving unit.
  • a method may include ingesting urea and inserting into the upper GI tract an in vivo sensing device. Endo-luminal pH or other enzymatic reaction products can be detected by the in vivo sensing device, thereby enabling in vivo detection of H. pylori.
  • the in vivo sensing device is an ingestible wireless device, which includes an appropriate sensor (such as a pH sensor) and which can transmit data (e.g. data regarding pH) to an external receiving unit, such as an ambulatory recorder.
  • the device may be wired to an external unit that receives data from the device.
  • the in vivo sensing device includes an imaging unit.
  • Figure 1 A is a schematic illustration of a system according to an embodiment of the invention.
  • Figure IB is a schematic illustration of a system according to further embodiments of the invention.
  • Figure 2 is a flow diagram illustrating steps of a method according to an embodiment of the invention.
  • Figure 3 is a schematic illustration of a system operative according to an embodiment of the invention.
  • FIG. 1A schematically illustrates a system according to an embodiment of the invention.
  • An in vivo device 10 is capable of detecting products 33 of the bacteria urease reaction in the stomach 20. If H. pylori is present in the stomach 20, urea, which is typically prevalent in the stomach, will be broken down by the bacteria urease. Alternatively, a patient may ingest urea and when the urea reaches the stomach 20 some of it reaches the stomach mucus 22 where, if H. pylori is present, the ingested urea will be broken down by the bacteria urease.
  • the enzymatic reaction is represented as follows:
  • the product 33 of the enzymatic reaction manifests itself in local pH changes and it is this parameter (pH) that is detected by the in vivo device 10.
  • this parameter pH
  • other products such as ammonia or bicarbonate molecules may be detected.
  • In vivo device 10 may be an in vivo pH meter, such as similar to the Heidelberg capsule or an ISFET pH meter that transmits radio wave signals of endo-luminal pH to an external receiving unit.
  • the in vivo device 10 includes an imaging system.
  • device 10 may be an autonomous self contained ingestible imaging capsule.
  • the capsule may be constructed similarly to capsules described in US Patent Number 5,604,531 and/or in WO 01/65995, both assigned to the common assignee of the present invention and hereby incorporated by reference.
  • An imaging system may include an illumination unit 23, typically comprising a plurality of illumination sources such as white LEDs, an image sensor 24, such as a CMOS or CCD, an optical system (not shown) for focusing an image onto the image sensor, a transmitter 26 for transmitting, such as by RF, image signals of the image sensor 24, and a power source 25, such as a silver oxide battery, that provides power to electrical elements of the imaging device.
  • the device 10 may transmit image and possibly other data to components located outside the patient's body, which receive and process the data.
  • the illumination unit 23 and image sensor 24 are both disposed behind an optical window 100.
  • pH-sensitive color-changing material 101 such as pH sensitive liquid crystal material (for example, crystal violet lactone) or litmus paper may be placed on the optical window 100.
  • the attachment or placement of the material 101 can be accomplished in several ways.
  • the material 101 may be in the form of a paint, and may be painted onto the capsule.
  • the material 101 is attached onto the capsule with adhesive.
  • the material 101 may be sprayed onto the capsule as a coating.
  • Other attaching methods are possible.
  • Light from the illumination unit 23 is directed towards the pH-sensitive color-changing material 101.
  • the illumination from the illumination unit 23 may be also used to illuminate the body lumen outside of the device 10, such as the stomach 20.
  • a separate illumination source may be included for that purpose.
  • the image sensor 24 may detect the color at each given point in time.
  • Transmitter 26 may transmit the color information to an external receiving unit.
  • a separate transmitter (not shown) may transmit pH data to an external receiving unit.
  • the color-changing material 101 is in the view of the image sensor 24.
  • a device such as the described capsule
  • it may proceed passively through the GI tract while images of the gastrointestinal tract wall and environment may be obtained simultaneously with images of the color-changing material 101. Any color or optical change, due to prevailing pH in the GI environment, will be visible in the images collected from the GI tract, according to one embodiment, providing the viewer with a pH map superimposed on the image.
  • basic pH spots e.g., patches of bacteria
  • the device 10 includes at least one sampling chamber 102.
  • the sampling chamber 102 is typically positioned in the field of illumination and in the field of view of the image sensor.
  • the sampling chamber 102 may be integrated into the device shell, optionally in the optical window 100.
  • Sample chamber 102 comprises a chamber cavity enclosed by two sides, a bottom and a membrane, the membrane typically constituting a partition between the body lumen environment and the chamber cavity.
  • at least the bottom of the chamber 102 may be transparent in the wavelength of illumination.
  • one or two of the sides are transparent in the illumination wavelength.
  • chamber 102 may comprise other components and have other shapes, such as a sack-like or cylindrical shape.
  • Sample chamber 102 which is typically configured for containing endo-luminal samples, such as body lumen fluids, may contain pH sensitive color changing particles, such that color may be apparent in the sample chamber dependant on the sample pH.
  • pH color indicators that may be utilized in this invention are typically weak acids whose colors differ in their dissociated (ionized) and neutral states, having pKa values of from about 6.5 to about 8.5. Typically, the indicators should change color over a pH range of from about 5.5 to about 9.0, preferably from over about 6.5. Examples of appropriate pH indicators may be bromothymol blue, phenol red, p-nitrophenol, neutral red, quinoline blue (cyanine), cresol red and thymol blue.
  • An endo-luminal sample may passively enter the chamber 102 through the membrane.
  • the sample may be actively drawn into the chamber 102, for example, based on osmotic pump technology, wherein flux of fluids into the chamber is typically a function of the membrane pore size and the outside to inside concentration gradient.
  • the sampling can be periodic, controlled, for example, by a switch. Local flux of the stomach environment and displacement of one sample from the sample chamber in favor of another sample may be effected, for example, by using a micro-pump.
  • the membrane of the chamber 102 may be fabricated from any suitable material, for example from silicon materials and may have any desired cut off size. According to one embodiment the membrane may be semi-permeable with a low molecular weight cut off, e.g. molecular weight of above about 100. According to another embodiment the membrane may be a microscopic mesh with pores in the order of microns. According to some embodiments pH sensitive particles may be immobilized in the chamber 102, such as by being immobilized to a chamber side or bottom or to an appendage that is restricted to the chamber. Chamber 102 may be illuminated by illumination unit 23 such that optical changes, typically as a result of pH or changes in the pH, which may occur in the sample contained in the chamber 102, may be detected by image sensor 24.
  • illumination unit 23 such that optical changes, typically as a result of pH or changes in the pH, which may occur in the sample contained in the chamber 102, may be detected by image sensor 24.
  • chamber 102 may be made of any suitable material such as plastic, glass etc. Parameters to be considered while assessing if a material is suitable may be, for example, the material's transparency, its safety for internal use, its durability under endo-luminal conditions and so on. Other sampling methods may be used.
  • device 10 is introduced into a body lumen, such as the stomach, and is preferably made to contact the lumen wall.
  • the lumen environment in the vicinity of the lumen wall is then sensed or sampled and analyzed. It has recently been discovered that H. pylori within the stomach is not continuous or in large areas, but rather patchy within the stomach wall. Having the device 10 contact the stomach mucus in a continuous track around the stomach wall or in a few spots along that track, may increase the probability that at least one area of H. pylori bacteria will be sampled or sensed.
  • the device 10 is an autonomous wireless device.
  • the device may be capsule shaped or any other suitable shape.
  • the device 10 may be ball shaped to enable rolling the device over the stomach wall with maximal contact points with the stomach mucus.
  • the device may be tethered, for example, tied to a string that may extend to the patient's mouth to enable holding the device from outside the patient's body to ensure the correct location of the device in the upper GI tract.
  • the device 10 may further comprise one or more appendages attached to the device housing to position and delay the device in the stomach.
  • oil may be administered to a patient to lengthen the device's stay in the patient's stomach.
  • the device may include a magnetic element that can be moved by an external magnetic field, thereby enabling to externally control the device and move it to desired parts of the stomach.
  • a receiving unit 1000 located outside the patient's body, are a receiving unit 1000, preferably including an antenna or antenna array 1002, for receiving image and possibly other data from an in vivo device, such as device 10, a receiver storage unit 1004, a data processor, such as processing unit 1006 and a display 1008, such as an image monitor, for displaying, inter alia, the images transmitted by the device 10 and recorded by the receiving unit 1000.
  • components of the receiving unit 1000 may be small and portable, and may be worn on a patient's body during receiving of in vivo data, such as during recording of the images.
  • antenna array 1002 may include one or more antennas that can be attached to a patient's stomach area, typically positioned to best receive data transmitted from the patient's stomach.
  • the antenna array 1002 may be part of a belt or garment worn about the relevant portion of a patient's body.
  • the processing unit 1006 and display 1008 may be part of a personal computer or workstation, which includes standard components such as a processor, a memory, a disk drive, and input-output devices, although alternate configurations are possible.
  • a receiving system similar to embodiments described in the above mentioned US Patent Number 5,604,531 and/or in WO 01/65995 may be used.
  • the processing unit 1006 is capable of being fed pH data and is capable of outputting indication of a pH or of a pH change which exceeds a predetermined threshold.
  • pH data from a patient's stomach can be transmitted to the receiving unit as described above, for example, as electronic signals that can be translated into pH values or as part of image data that is being transmitted from an in vivo imaging system.
  • the processing unit 1006 is capable of indicating a pH value that is equal to or larger than about 5.5.
  • the processing unit 1006 is capable of calculating a pH change and indicating when this change exceeds a threshold.
  • a threshold can be determined as the difference between a normal stomach pH (which is about 2.0 - 3.0) and a more basic area (e.g., 5.5), which typically indicates the presence of H. pylori, according to embodiments of the invention.
  • a threshold of over about 2.5 may be indicated as a sign for the presence of the bacteria.
  • a threshold may be determined according to calibration procedures.
  • indication of a pH value or pH change is relayed to display 1008.
  • the display 1008 may include any suitable display means such as an image monitor, a graphic display, a light indicator an audio display, a vibrating mechanism, and so on.
  • components of the receiving unit 1000 may be part of one unit or work station or may be separate units which are in electric communication, for example, by a wired or wireless connection.
  • a patient ingests urea, preferably in liquid form, for example, in a volume of 50ml.
  • the urea reaches the stomach and may come in contact with the stomach mucus.
  • urea is suspended in oil, such that it is delayed in the stomach.
  • urea can be added to heavy beads that will bring the urea to the stomach wall.
  • it is not necessary to ingest urea. Normally prevailing urea may be used by the bacteria to produce bases.
  • an in vivo device- such as an imaging device having intrinsic pH sensing capabilities (for example, as described above) - is inserted into the patient's upper GI tract, for example into the stomach.
  • the device may be inserted by ingesting the device, by placing it, for example with the aid of an endoscope, and so on.
  • in vivo data is transmitted from the device.
  • pH data is transmitted to an external receiving unit.
  • images of the stomach are obtained and transmitted to an external operator either on line or off line (for example, images are transmitted to a recorder which is reviewed only later).
  • images obtained by devices such as described above also include pH data (for example, color indication of the prevailing pH in areas of the stomach).
  • the prevailing pH may be an indicator of the presence of H. pylori, since relatively basic areas are expected due to H. pylori enzymatic activity.
  • the prevailing pH can be visualized and therefore also the presence of H.
  • An additional step (240), according to some embodiments of the invention, includes causing the in vivo device to contact the stomach wall (preferably, the stomach mucus) in at least one spot.
  • this step may include mixing and/or increasing pressure in the stomach lumen.
  • This may cause an autonomous in vivo sensing device that is situated in the stomach to be pushed to the stomach wall and to contact it.
  • a patient may intake a carbonated beverage prior to inserting an in vivo sensing device.
  • the carbonated beverage typically causes an increased pressure in the stomach.
  • a carbonated beverage, or any other suitable solution may induce belching, which typically causes movement and turbulence of the stomach content in addition to causing increased pressure, so as to move an autonomous in vivo sensing
  • an in vivo sensing device such as a capsule as described above, which is
  • Procedure 2 for positioning a patient so as to ensure contact of an autonomous pH
  • the patient is positioned Back Trendelenburg -10 degrees for about 1 minute; 3.
  • the patient is positioned on his left side with his head elevated at 45 degrees for about 1 minute;
  • the patient is positioned on his left side with his head elevated at 60 degrees for about 1 minute; 5. The patient is positioned on his left side with his head elevated at 80 degrees for about 1 minute;
  • Fig. 3 schematically illustrates a swallowable capsule having pH sensing capabilities that is moved about a patient's stomach according to an embodiment of the invention, for example, according to the above Procedure 2. It can be seen that the capsule follows a track that covers most of the stomach body, including remote areas such as the cardia, fundum, antrum and the pyloric canal. It will be appreciated that rotating the patient causes the capsule to be moved by its own weight and to rest directly on the stomach wall (mucus) at each position. It will be appreciated by persons skilled in the art that the present invention is not limited by what has been particularly shown and described herein above. Rather the scope of the invention is defined by the claims, which follow.

Abstract

La présente invention concerne une méthode et un système de détection in vivo de H.pylori. La méthode selon une forme de réalisation consiste à mesurer le pH à au moins un endroit proche d'un mucus gastrique du patient et à transmettre par radiofréquence les données de pH à une unité de réception externe. Les données de pH peuvent faire partie d'une image in vivo.
PCT/IL2003/000893 2002-10-31 2003-10-30 Systeme et methode de detection in vivo de h. pylori WO2004039233A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2003278576A AU2003278576A1 (en) 2002-10-31 2003-10-30 System and method for in vivo detection of h. pylori
US10/532,808 US20060052667A1 (en) 2002-10-31 2003-10-30 System and method for in vivo detection of h. pylori

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42248302P 2002-10-31 2002-10-31
US60/422,483 2002-10-31

Publications (2)

Publication Number Publication Date
WO2004039233A2 true WO2004039233A2 (fr) 2004-05-13
WO2004039233A3 WO2004039233A3 (fr) 2004-06-24

Family

ID=32230359

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2003/000893 WO2004039233A2 (fr) 2002-10-31 2003-10-30 Systeme et methode de detection in vivo de h. pylori

Country Status (3)

Country Link
US (1) US20060052667A1 (fr)
AU (1) AU2003278576A1 (fr)
WO (1) WO2004039233A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1767136A1 (fr) * 2004-06-16 2007-03-28 Olympus Corporation Couverture d'antenne et dispositif d'antenne
US7460896B2 (en) 2003-07-29 2008-12-02 Given Imaging Ltd. In vivo device and method for collecting oximetry data
WO2009127528A1 (fr) * 2008-04-18 2009-10-22 Siemens Aktiengesellschaft Capsule endoscopique
WO2011141372A1 (fr) * 2010-05-14 2011-11-17 Siemens Aktiengesellschaft Capsule endoscopique permettant d'identifier un métabolite d'un excitateur se trouvant dans ou sur une paroi d'un organe creux du tractus gastro-intestinal d'un homme ou d'un animal

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080045788A1 (en) * 2002-11-27 2008-02-21 Zvika Gilad Method and device of imaging with an in vivo imager
US9801527B2 (en) 2004-04-19 2017-10-31 Gearbox, Llc Lumen-traveling biological interface device
JP2008501466A (ja) * 2004-06-07 2008-01-24 ギブン イメージング リミテッド 吸引生体検査法、システムおよび装置
WO2006005075A2 (fr) * 2004-06-30 2006-01-12 Amir Belson Appareil et methodes pour une endoscopie par capsule de l'oesophage
JP4445812B2 (ja) * 2004-07-08 2010-04-07 オリンパス株式会社 被検体内導入装置および被検体内導入システム
US20080058785A1 (en) * 2006-04-12 2008-03-06 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Autofluorescent imaging and target ablation
WO2009060460A2 (fr) * 2007-11-09 2009-05-14 Given Imaging Ltd. Appareil et procédés pour une endoscopie par capsule de l'œsophage
AU2017312662B2 (en) * 2016-08-18 2022-09-08 Biora Therapeutics, Inc. Sampling systems and related materials and methods
KR102379748B1 (ko) * 2020-07-13 2022-03-29 재단법인대구경북과학기술원 헬리코박터 파일로리 진단캡슐
US11202558B1 (en) * 2021-05-12 2021-12-21 Shenzhen Jifu Medical Technology Co., Ltd Interactive magnetically controlled capsule endoscope automatic cruise examination system

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5657759A (en) * 1993-05-13 1997-08-19 Synectics Medical, Incorporated Measurement of gastric emptying and gastrointestinal output
US5787885A (en) * 1994-10-13 1998-08-04 Lemelson; Jerome H. Body fluid analysis system
US6391558B1 (en) * 1997-03-18 2002-05-21 Andcare, Inc. Electrochemical detection of nucleic acid sequences

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4932412A (en) * 1986-12-18 1990-06-12 Immunomedics, Inc. Intraoperative and endoscopic tumor detection and therapy
US6096289A (en) * 1992-05-06 2000-08-01 Immunomedics, Inc. Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
EP0643583B1 (fr) * 1992-05-06 2000-07-26 Immunomedics, Inc. Detection et therapie de tumeurs et de lesions pendant un examen peroperatoire, intravasculaire et endoscopique
AU8127094A (en) * 1993-10-28 1995-05-22 Barry Marshall Detection of h. pylori in the stomach
IL108352A (en) * 1994-01-17 2000-02-29 Given Imaging Ltd In vivo video camera system
US6479278B2 (en) * 1995-06-13 2002-11-12 Barry Marshall Detection of Helicobacter pylori in the stomach
US8636648B2 (en) * 1999-03-01 2014-01-28 West View Research, Llc Endoscopic smart probe
WO2001053792A2 (fr) * 2000-01-19 2001-07-26 Given Imaging Ltd. Systeme de detection de substances
CA2435205A1 (fr) * 2001-01-22 2002-08-01 V-Target Technologies Ltd. Dispositif ingerable
WO2004058043A2 (fr) * 2002-12-30 2004-07-15 Given Imaging Ltd. Methode de detection in vivo
US7628753B2 (en) * 2002-12-30 2009-12-08 Given Imaging, Ltd. Method for in vivo sensing

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5657759A (en) * 1993-05-13 1997-08-19 Synectics Medical, Incorporated Measurement of gastric emptying and gastrointestinal output
US5787885A (en) * 1994-10-13 1998-08-04 Lemelson; Jerome H. Body fluid analysis system
US6391558B1 (en) * 1997-03-18 2002-05-21 Andcare, Inc. Electrochemical detection of nucleic acid sequences

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE ON NCBI KELLY D J: 'THE PHYSIOLOGY AND METABOLISM OF THE HUMAN GASTRIC PATHOGEN HELICOBACTER PYLORI', XP002977250 Database accession no. 9889978 & ADV. MICROB PHYSIOL. vol. 40, 1998, pages 137 - 189 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7460896B2 (en) 2003-07-29 2008-12-02 Given Imaging Ltd. In vivo device and method for collecting oximetry data
EP1767136A1 (fr) * 2004-06-16 2007-03-28 Olympus Corporation Couverture d'antenne et dispositif d'antenne
EP1767136A4 (fr) * 2004-06-16 2007-11-28 Olympus Corp Couverture d'antenne et dispositif d'antenne
US7456801B2 (en) 2004-06-16 2008-11-25 Olympus Corporation Antenna cover and antenna apparatus
US7804462B2 (en) 2004-06-16 2010-09-28 Olympus Corporation Antenna cover and antenna apparatus
US7804461B2 (en) 2004-06-16 2010-09-28 Olympus Corporation Antenna cover and antenna apparatus
WO2009127528A1 (fr) * 2008-04-18 2009-10-22 Siemens Aktiengesellschaft Capsule endoscopique
CN102006822A (zh) * 2008-04-18 2011-04-06 西门子公司 胶囊内窥镜
JP2011516226A (ja) * 2008-04-18 2011-05-26 シーメンス アクチエンゲゼルシヤフト 特定の細菌の検出方法および体内カプセル
WO2011141372A1 (fr) * 2010-05-14 2011-11-17 Siemens Aktiengesellschaft Capsule endoscopique permettant d'identifier un métabolite d'un excitateur se trouvant dans ou sur une paroi d'un organe creux du tractus gastro-intestinal d'un homme ou d'un animal
CN102985006A (zh) * 2010-05-14 2013-03-20 西门子公司 用于检测处在人或动物胃肠道的中空器官壁之中或之上的病原体代谢产物的内窥镜胶囊

Also Published As

Publication number Publication date
AU2003278576A1 (en) 2004-05-25
US20060052667A1 (en) 2006-03-09
AU2003278576A8 (en) 2004-05-25
WO2004039233A3 (fr) 2004-06-24

Similar Documents

Publication Publication Date Title
EP1350103B1 (fr) Systeme de detection de substances
US8911368B2 (en) Device, system and method for detection of bleeding
CN103827668B (zh) 用于体内免疫测定的装置、系统和方法
EP1358460B1 (fr) Systeme permettant de determiner des conditions de lumieres corporelles in vivo
JP5595378B2 (ja) 特定の細菌の検出方法および体内カプセル
US20060052667A1 (en) System and method for in vivo detection of h. pylori
EP1534120B1 (fr) Systeme d'echantillonnage et d'analyse in vivo
US8738106B2 (en) Device, system and method for in vivo analysis
JP5275217B2 (ja) 生体内分析のためのシステム
US8290556B2 (en) Device, system and method for in-vivo analysis
EP2007433B1 (fr) Dispositif, systeme et procede pour une analyse in vivo
AU2002225316A1 (en) A system and method for determining in vivo body lumen conditions
JP2006509574A (ja) 生体内センサの選択的作動のための装置、システム、及び方法
EP1843697A2 (fr) Dispositif, systeme et procede d'analyse in vivo
JPH0695960B2 (ja) ウレア−ゼを検出するための組成物、方法および装置
WO2009057120A2 (fr) Dispositif, système et procédé d'analyse in vivo
Liu et al. A smart capsule system of gastric occult blood detection
EP1331881A1 (fr) Images fluorescentes de transmission video d'une capsule ingestible
US20240023845A1 (en) Medical detection apparatus and measuring component thereof
Abdigazy et al. End-to-end design of ingestible electronics
IL150810A (en) Material identification system
IL194468A (en) In vitro testing device
IL156962A (en) A system and method for determining the state of cavities in the animal body

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2006052667

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10532808

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 168283

Country of ref document: IL

122 Ep: pct application non-entry in european phase
WWP Wipo information: published in national office

Ref document number: 10532808

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP